Adverse events (AE)
Ten studies provided enough information on the occurrence of AEs. No
statistically significant difference on the occurrence of AE was
observed between the use of omalizumab vs. placebo (RR=1.03; 95% CI,
0.93, 1.14; p=0.618; I2 = 43.3%). (Figure 6).
Supplementary Table III presents the AEs of the included trials
classified in system organ classes based on Medical Dictionary for
Regulatory Activities version 23 (MedDRA v.23). Serious AEs of the
included trials are presented in Table 2.